Tanabe Pharma America

Focus: Tanabe Pharma America is a specialty pharmaceutical subsidiary focused on small-molecule therapeutics in neurology, anchored by RADICAVA for ALS. The company operates as part of Tanabe Seiyaku's global footprint with US headquarters in Jersey City, NJ.

Neurology

Profile data last refreshed 5h ago · AI intelligence enriched 2w ago

Open Jobs

About Tanabe Pharma America

AI assessmentNot Hiring

No open roles listed right now. Follow Tanabe Pharma America to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

7 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

RADICAVA

Amyotrophic lateral sclerosis (ALS)

$11M Part D

Peak

Only approved therapy driving 100% of company revenue; available in both IV (RADICAVA) and oral (RADICAVA ORS) formulations.

Products & Portfolio (1)

Help build intelligence for Tanabe Pharma America

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Edaravone

Amyotrophic Lateral Sclerosis

N/A

Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)

ALS (Amyotrophic Lateral Sclerosis)

N/A

Clinical Trials (1)

NCT05276349Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)

N/A

Analysis of Human ALS Tissues and Registry of ALS Patients

Amyotrophic Lateral Sclerosis

N/A

Clinical Trials (1)

NCT05067179Analysis of Human ALS Tissues and Registry of ALS Patients

N/A

Spirometry

Amyotrophic Lateral Sclerosis

N/A

Clinical Trials (1)

NCT05106569Telespirometry in Amyotrophic Lateral Sclerosis (ALS)

N/A

[14C] MT-8554

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03381404Mass Balance Study With MT-8554

Phase 1

MT-7117

Mild and Moderate Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT04116476Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Phase 1

MT-8554 Low dose

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03471130Definitive QT Study With MT-8554

Phase 1

MT-7117

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT04793295Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects

Phase 1

MT-7117

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03688022Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor

Phase 1

[14C] MT-7117

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT03503266Mass Balance Study With MT-7117

Phase 1

MT-7117

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT05241535Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Phase 1

MT-6345

Healthy

Phase 1

Clinical Trials (1)

NCT03809039A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

Phase 1

MT-7117

Renal Impairment

Phase 1

Clinical Trials (1)

NCT04656795PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Phase 1

MT-3921 Low dose

Spinal Cord Injury

Phase 1

Clinical Trials (1)

NCT04096950Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

Phase 1

MT-4561

Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1/2

Clinical Trials (1)

NCT06943521A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Phase 1/2

MT-3921

Spinal Cord Injury

Phase 2

Clinical Trials (1)

NCT04683848Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

Phase 2

MT-7117 low dose

Erythropoietic Protoporphyria (EPP)

Phase 2

Clinical Trials (1)

NCT03520036Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Phase 2

MT-7117

Diffuse Cutaneous Systemic Sclerosis

Phase 2

Clinical Trials (1)

NCT04440592Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Phase 2

MT-2990

Endometrial Related Pain

Phase 2

Clinical Trials (1)

NCT03840993Safety and Efficacy Study of MT-2990 in Women With Endometriosis

Phase 2

MT-8554 1mg

Menopause Hot Flashes

Phase 2

Clinical Trials (1)

NCT03291067MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Phase 2

MT-8554

Vasomotor Symptoms (VMS)

Phase 2

Clinical Trials (1)

NCT03541200Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

Phase 2

Placebo

EPP

Phase 3

Clinical Trials (1)

NCT04402489Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

Phase 3

MT-1186

ALS

Phase 3

MT-1186

Amyotrophic Lateral Sclerosis (ALS)

Phase 3

MT-7117

EPP

Phase 3

Clinical Trials (1)

NCT05005975Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Phase 3

MT-1186

ALS

Phase 3

Clinical Trials (1)

NCT05151471Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

Phase 3

MT-1186

ALS

Phase 3

Dersimelagon

Erythropoietic Protoporphyria (EPP)